Clinical data for cabozantinib to be presented at ASCO annual meeting

[News]

Exelixis, Inc. announced today that its lead compound, cabozantinib, will be the subject of nine separate data presentations at the upcoming Annual Meeting of the American Society of Clinical Oncology.

More... (http://www.news-medical.net/news/20120402/Clinical-data-for-cabozantinib-to-be-presented-at-ASCO-annual-meeting.aspx)